Search results
Showing 16 to 30 of 32 results for pomalidomide
Discontinued [GID-TA10353]
Managed access allows patients to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.
Lenalidomide plus dexamethasone for previously untreated multiple myeloma (TA587)
Evidence-based recommendations on lenalidomide (Revlimid) plus dexamethasone for previously untreated multiple myeloma in adults.
Evidence-based recommendations on Ixazomib (Ninlaro) with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma.
Hundreds of people with multiple myeloma could receive a new, targeted treatment recommended for use within the Cancer Drugs Fund today (Tuesday, 29 October).
Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma (TA695)
Evidence-based recommendations on carfilzomib (Kyprolis) with dexamethasone and lenalidomide (Revlimid) for previously treated multiple myeloma in adults.
Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib (TA586)
Evidence-based recommendations on lenalidomide (Revlimid) plus dexamethasone for multiple myeloma after 1 treatment with bortezomib in adults.
Relapsed and refractory multiple myeloma: pomalidomide (ESNM32)
This evidence summary has been replaced by NICE technology appraisal guidance 338 [Replaced by NICE technology appraisal guidance 427]
Pembrolizumab for previously treated multiple myeloma (ID1139)
Discontinued [GID-TA10193]
This guideline covers assessing and reducing the risk of venous thromboembolism (VTE or blood clots, including deep vein thrombosis and pulmonary embolism) in people aged 16 and over in hospital. It aims to help healthcare professionals identify people most at risk and describes interventions that can be used to reduce the risk of VTE.
Evidence-based recommendations on carfilzomib (Kyprolis) for previously treated multiple myeloma in adults.
In development [GID-TA10568] Expected publication date: TBC
This guidance has been updated and replaced by NICE technology appraisal guidance 427.
Evidence-based recommendations on daratumumab (Darzalex) for newly diagnosed systemic amyloid light-chain amyloidosis in adults.
Evidence-based recommendations on avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy in adults.